Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|180|5|757-760

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.180, Iss.5, 2018-03, pp. : 757-760

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 4, 2015-04 ,pp. : E73-E73

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of EBV‐associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 11, 2015-11 ,pp. : 2018-2020

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of EBV‐associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 1545-5009, Iss. 11, 2015-11 ,pp. : 2018-2020

John Wiley & Sons Inc

Access to resources Recommend Favorite

Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post‐transplantation

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 6, 2015-06 ,pp. : 1063-1065

John Wiley & Sons Inc

Access to resources Recommend Favorite

The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : 571-571

John Wiley & Sons Inc

Access to resources Recommend Favorite